Retacrit and Heart attack - a phase IV clinical study of FDA data

Summary:

Heart attack is reported as a side effect among people who take Retacrit (epoetin alfa-epbx), especially for people who are female, 60+ old, also take Bactrim, and have Anaemia.

The phase IV clinical study analyzes which people have Heart attack when taking Retacrit. It is created by eHealthMe based on reports of 2,195 people who have side effects when taking Retacrit from the FDA, and is updated regularly.

What is Retacrit?

Retacrit has active ingredients of epoetin alfa-epbx. eHealthMe is studying from 2,196 Retacrit users. Check the latest studies of Retacrit.

What is Heart attack?

Heart attack is found to be associated with 2,475 drugs and 3,298 conditions by eHealthMe. Check the latest studies of Heart attack.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

2,195 people reported to have side effects when taking Retacrit.
Among them, 11 people (0.5%) have Heart attack.

Among these 11 people:

What is the gender of people who have Heart attack when taking Retacrit? *

female: 70 %
male: 30 %

What is the age of people who have Heart attack when taking Retacrit? *

What are other drugs people take besides Retacrit? *

What are other side effects people have besides Heart attack? *

Pneumonia: 2 people, 18.18%
Hypovolaemic Shock (shock caused by severe blood or fluid loss): 2 people, 18.18%
Dizziness: 2 people, 18.18%
Cataract (clouding of the lens inside the eye): 1 person, 9.09%
Blood Pressure Abnormal: 1 person, 9.09%
Anaemia (lack of blood): 1 person, 9.09%

What are the existing conditions these people have? *

Anaemia (lack of blood): 3 people, 27.27%
Multiple Myeloma (cancer of the plasma cells): 2 people, 18.18%
Primary Myelofibrosis (primary disorder of the bone marrow): 1 person, 9.09%
Nephrogenic Anaemia (anaemia due to kidney disease): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Retacrit and have Heart attack?

- Check whether Heart attack is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Retacrit:

Retacrit (2,196 reports)

Heart attack treatments and more:

Heart attack (266,145 reports)

Browse all side effects of Retacrit:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Heart attack:

Heart attack (2,475 drugs)

Browse all the conditions that are associated with Heart attack:

Heart attack (3,298 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on epoetin alfa-epbx (the active ingredients of Retacrit) and Retacrit (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.